Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Almirall

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Almirall's 2013 sales performance.

New hires at Crescendo, Healx and Galecto

New hires at Crescendo, Healx and Galecto

Before that, he lead global R&D at Almirall, which involved 500 staff and the development and approval of several new drugs in a number of therapy areas.

Almirall eyes $62m takeover of multicytokine specialist Bioniz

Almirall eyes $62m takeover of multicytokine specialist Bioniz Barcelona-based Almirall – which specialises in dermatology – says that the deal would expand its R&D pipeline with an additional three candidates on top of lead drug BNZ-1. ... Meanwhile, Almirall is in the launch phase for Ilumya/Ilumetri

Amgen buys Danish partner Nuevolution for $167m

Amgen buys Danish partner Nuevolution for $167m It will inherit established partnerships that Nuevolution also signed with the likes of Almirall, and Johnson &Johnson, according to the Danish firm’s website, and analysts at Edison said in March ... The Almirall partnership includes a RORγt

Big Pharma, Little Pharma

Big Pharma, Little Pharma And that’s exactly what comes out of my research. The recent industry announcement that triggered this thought was from Almirall, the Spanish pharma company with fewer than 2, 000 employees

Almirall acquires Allergan’s dermatology portfolio for $650m

Almirall acquires Allergan’s dermatology portfolio for $650m In a deal worth $650m, Spanish pharmaceutical company Almirall is set to buy Allergan’s US-based medical dermatology unit. ... If approved, Seysara could pull in predicted annual sales of $200m for Almirall.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics